SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-071880
Filing Date
2022-06-16
Accepted
2022-06-16 16:06:04
Documents
12
Period of Report
2022-06-16
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2218670d1_8k.htm   iXBRL 8-K 30458
  Complete submission text file 0001104659-22-071880.txt   202895

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cldx-20220616.xsd EX-101.SCH 3066
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE cldx-20220616_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cldx-20220616_pre.xml EX-101.PRE 22617
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2218670d1_8k_htm.xml XML 3518
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-15006 | Film No.: 221020579
SIC: 2835 In Vitro & In Vivo Diagnostic Substances